Due to pending storm, NYOH offices will open at 10am on Friday, November 16th.

Clinical Trials & Research

Home / Clinical Trials & Research / View Open Trials

View Open Trials

Bladder
Breast
Head and Neck
Lung (Non Small Cell)
Lymphomas
Melanoma
Myelomas
Other
Pancreatic
Prostate
Solid Tumors

Bladder

  • NeoAdj Chemo +/- Nivo/IDO1inh MIBC

    A Phase 3, Randomized, Open-Label Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

  • Sitravatinib + Nivo Adv/Met Urothelial

    A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

  • Ph2 Rucaparib mUC

    ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (CO-338-085)

  • Ph2 enfortumab (ASG-22CE) Urothelial

    A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • INCB054828 Urothelial FGF/FGFR

    A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

  • RdDbBlnd NivovsPlbo HighRiskMI Urothl

    A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma- Bristol-Myers Squibb CA209-274

Breast

  • Ph1/2 Ibrutinib+Tras HER2 amp/MBC

    Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

  • Ph 3 Tesetaxel+Capecitabine mHER2-

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

  • Sacituzumab Govitecan vs PhyChoic TNBC

    An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

  • Ph3 Abemaciclib HR+ HER2- (MonarchE)

    (I3Y-MC-JPCF)A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

  • Cape/tras +/- ONT-380 HER2+ mBC

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206)

Head and Neck

  • Ph3 Atezo SCC H&N

    A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH RISK LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (WO40242)

Lung (Non Small Cell)

  • Ph2 Poziotinib EGFR/HER2 NSCLC

    A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

  • Ph3 Adj canakinumab NSCLC

    A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

  • VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC

    Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)

  • Ph3 Nivo vs Plat-Doublet chemo NSCLC

    Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

  • BSC +/- LAN in Lung NETs [SPINET]

    USO 15079 A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg plus BSC vs. Placebo plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (Spinet) - Ipsen A-US-52030-328

Lymphomas

Melanoma

Myelomas

  • Ph3 Dara high-risk SMM

    A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma (54767414SMM3001)

  • Ph3 Dara high-risk SMM

    A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma (54767414SMM3001)

  • Dara + CyBorD 1L & Relapsed MM [LYRA]

    Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD)in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012)

Other

  • Ph2 Itacitinib +/- Ruxo in MF

    An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

    The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.

  • Nivo in Advanced/Met Malignancies

    An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Pancreatic

  • Ph2 SM88 Pancreatic

    Tyme-88-Panc: A Phase II Multi-Center Study of SM88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy

Prostate

  • Ph2 Nivo mCRPC (CheckMate 9KD)

    A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)

  • Rucaparib v PhysC mCRPC (TRITON3)

    TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

Solid Tumors